(New Brunswick, NJ) — The U.S. could be a step closer to getting a third coronavirus vaccine. Staff at the Food and Drug Administration say Johnson & Johnson’s single-dose vaccine meets the requirements for emergency use. Staff explained the results from the clinical trial and its safety data were consistent with the F-D-A’s COVID guidance recommendations. An F-D-A advisory committee will meet Friday to review the company’s request for emergency use authorization. Johnson & Johnson explained the vaccine’s level of protection was 72-percent effective in the U.S. while also preventing 100-percent of hospitalizations and deaths. There were no reports of any allergic reaction.